by Eric Christianson | Sep 15, 2024 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Many drugs cause insomnia. What is most frustrating to me in my practice is when we start medications for a “new condition” prior to ruling out medication adverse effects. Here is the list of my top 5 drugs that cause insomnia (an important adverse...
by Eric Christianson | Sep 11, 2024 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Opvee (nalmefene), is an intranasal opioid antagonist used for opioid overdose and was approved by the FDA in 2023. This approval provided another tool to aid in combating the opioid crisis. There are currently two medications, Opvee and Narcan (naloxone), that can...
by Eric Christianson | Sep 8, 2024 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
In this blog post, I want to share some important SSRI clinical pearls that help clinicians decide which of these antidepressants to use. Note that these clinical practice pearls are good examples of some testable items that may show up on your board exam 🙂 Sertraline...
by Eric Christianson | Jul 28, 2024 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
We will compare aripiprazole versus risperidone and why a clinician might recommend one versus another. These two agents are two of the most commonly used antipsychotics in practice. Antipsychotics are most often used for psychiatric disorders like schizophrenia and...
by Eric Christianson | Jul 21, 2024 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Paroxetine is from the family of SSRIs (selective serotonin reuptake inhibitors. It has been around for a long time and is indicated for depression, anxiety, and many other psychiatric indications just like other SSRIs. It doesn’t get much love from healthcare...
by Eric Christianson | Jun 26, 2024 | Clinical Pharmacy News and New Drug Updates, Psychiatry and Addiction Medication and Disease State Clinical Pearls
I’ve encountered a significant proportion of patients who are on chronic benzodiazepines. Drug interactions, adverse effects, and other risks to my geriatric patient population are significant when using this class of medication. Benzodiazepine withdrawal is...
